Using standard-of-care screening to identify inequities in cancer-related financial hardship.

Authors

Courtney Williams

Courtney Williams

University of Alabama at Birmingham, Birmingham, AL

Courtney Williams, Margaret Irene Liang, Gabrielle Betty Rocque, Risha Gidwani, Nicole E. Caston, Maria Pisu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care

Sub Track

Interventions and Policies to Optimize Health Equity

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 196)

DOI

10.1200/OP.2023.19.11_suppl.196

Abstract #

196

Poster Bd #

F7

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Quality Care Symposium

National service is free, not cancer disease: Financial toxicity in a public universal coverage healthcare system.

National service is free, not cancer disease: Financial toxicity in a public universal coverage healthcare system.

First Author: Paola Russo

Poster

2021 ASCO Quality Care Symposium

Assessing effectiveness of a self-guided training program for oncology financial advocates.

Assessing effectiveness of a self-guided training program for oncology financial advocates.

First Author: Christina Mangir

Poster

2024 ASCO Genitourinary Cancers Symposium

Comparison of financial toxicity among patients with non-metastatic versus metastatic renal cell carcinoma.

Comparison of financial toxicity among patients with non-metastatic versus metastatic renal cell carcinoma.

First Author: Michael D. Staehler

Poster

2024 ASCO Genitourinary Cancers Symposium

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

First Author: David Joseph Benjamin